Marbotab 20 mg Tablets for Dogs and Cats
Country: Ireland
Language: English
Source: HMA (Heads of Medicines Agencies)
Summary of Product characteristics
(SPC)
28-03-2013
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
marbofloxacin 20 mg
Available from:
CP Pharma Handelsgesellschaft mbH
ATC code:
QJ01MA93
Pharmaceutical form:
Tablet
Therapeutic group:
marbofloxacin
Therapeutic area:
Cats, Dogs
Authorization date:
2012-12-21
Summary of Product characteristics
Issued: March 2013
AN: 01688/2011
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Marbotab P 20 mg tablets for dogs and cats
List of agreed names in the Member States where product is authorized.
Italy, Germany, France, The Netherlands,
Belgium, Hungary
Marbotab P 20 mg tablets for dogs and
cats
Denmark
Marbotab P, 20 mg tablets, for dogs and
cats
United Kingdom, Ireland, Poland, Spain,
Austria
Marbotab 20 mg tablets for dogs and cats
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE:
Marbofloxacin
20 mg
EXCIPIENTS:
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Beige tablets with white speckled, cross-snap-tab.
The tablets can be divided into quarters.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs, cats
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of infections caused by strains of microorganisms susceptible to
marbofloxacin.
IN DOGS:
Skin and soft tissue infections (skinfold pyoderma, impetigo, folli culitis,
furunculosis, cellulitis);
Urinary tract infections (UTI) associated or not with prostatitis;
Respiratory tract infections.
Issued: March 2013
AN: 01688/2011
Page 2 of 6
IN CATS:
Skin and soft tissue infections (wounds, abscesses, phlegmons);
Upper respiratory tract infections.
See section 5.1, Pharmacodynamic properties for further information on specific
target pathogens.
4.3
CONTRAINDICATIONS
Marbofloxacin should not be
Read the complete document
